Finepoint Capital’s Cytokinetics CYTK Stock Holding History

Finepoint Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-309,948	Closed	-$12.5M	–	13
2025 Q1	$12.5M	Sell	309,948 -8,500	-3%	-$391K	0.95%	11
2024 Q4	$15M	Buy	318,448 +61,999	+24%	+$3.22M	0.91%	14
2024 Q3	$13.5M	Hold	256,449	–	–	0.98%	15
2024 Q2	$13.9M	Buy	256,449 +18,403	+8%	+$1.11M	3.94%	11
2024 Q1	$16.7M	Sell	238,046 -193,647	-45%	-$15M	4.28%	9
2023 Q4	$36M	Hold	431,693	–	–	11.37%	1
2023 Q3	$12.7M	Buy	431,693 +62,600	+17%	+$2.08M	6.33%	8
2023 Q2	$12M	Sell	369,093 -44,700	-11%	-$1.65M	4.17%	14
2023 Q1	$14.6M	Buy	413,793 +11,000	+3%	+$449K	5.56%	12
2022 Q4	$18.5M	Buy	402,793 +22,000	+6%	+$947K	5.97%	5
2022 Q3	$18.4M	Sell	380,793 -38,640	-9%	-$1.86M	6.07%	4
2022 Q2	$16.5M	Buy	+419,433	New	+$16.9M	5.7%	4

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Finepoint Capital's CYTK Position: Q2 2025 in Review

Finepoint Capital sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 309,948 shares — an estimated $12.5M sold.

Finepoint Capital first reported a position in CYTK in Q2 2022 and held it in 12 quarters. The position peaked at $36M in Q4 2023. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Finepoint Capital reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Finepoint Capital sold 309,948 Cytokinetics shares in Q2 2025, an estimated $12.5M.
Finepoint Capital first reported a position in Cytokinetics in Q2 2022 and held it in 12 quarters.
Finepoint Capital's Cytokinetics position peaked at $36M in Q4 2023.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.